Comparison of Olmesartan Medoxomil Versus Amlodipine Besylate on Regression of Ventricular and Vascular Hypertrophy

Rosendorff, Clive; Dubiel, Robert; Xu, Jianbo; Chavanu, Kathleen J.

doi:10.1016/j.amjcard.2009.03.042

Cited by 13 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Olmesartan, clinically used as an angiotensin II receptor blocker, plays a critical role in preventing cardiac hypertrophy by exerting its inhibitory effects on the angiotensin II receptor which is an important component of the renin-angiotensin system (RAS) [9]. Olmesartan may also have anti-oxidant and anti-inflammatory effects on patients with heart failure [10].…”

Section: Introductionmentioning

confidence: 99%

Olmesartan Attenuates the Impairment of Endothelial Cells Induced by Oxidized Low Density Lipoprotein through Downregulating Expression of LOX-1

Zhang

Yao

et al. 2012

IJMS

View full text Add to dashboard Cite

Oxidized low density lipoprotein (ox-LDL) and its receptor, lectin-Like ox-LDL receptor-1 (LOX-1), play important roles in the development of endothelial injuries. Olmesartan can protect endothelial cells from the impairment caused by various pathological stimulations. In the present study we investigated whether olmesartan decreased the impairment of endothelial cells induced by ox-LDL by exerting its effects on LOX-1 both in vitro and in vivo. Incubation of cultured endothelial cells of neonatal rats with ox-LDL for 24 h or infusion of ox-LDL in mice for 3 weeks led to the remarkable impairment of endothelial cells, including increased lactate dehydrogenase synthesis, phosphorylation of p38 mitogen-activated protein kinases (p38 MAPK) and expression of apoptotic genes such as B-cell leukemia/lymphoma 2 (Bcl-2)-associated X protein (Bax) and caspase-3. Simultaneously, the cell vitality and expression of Bcl-2 gene were greatly reduced. All these effects, however, were significantly suppressed by the treatment with olmesartan. Furthermore, ox-LDL promoted up-regulation of LOX-1 expression either in cultured endothelial cells or in the aortas of mice, which was reversed with the administration of olmesartan. Our data indicated that olmesartan may attenuate the impairment of endothelial cell via down-regulation of the increased LOX-1 expression induced by ox-LDL.

show abstract

Section: Introductionmentioning

confidence: 99%

Olmesartan Attenuates the Impairment of Endothelial Cells Induced by Oxidized Low Density Lipoprotein through Downregulating Expression of LOX-1

Zhang

Yao

et al. 2012

IJMS

View full text Add to dashboard Cite

show abstract

“…Correlation between SBP and LVMI was found to be 0.17 and 0.2 in losartan and amlodipine, respectively (Table 9); correlation between DBP and LVMI was found to be 0.21 in losartan patients and 0.41 in amlodipine patients (Table 10). The ADR events of both groups were monitored and it was observed that only patients in amlodipine group experienced ADR such as peripheral edema [22], which was comparable with ADR occurred in Rosendorff et al's [23] study.…”

Section: Rutuparna Et Almentioning

confidence: 82%

Assesment of Clinical Effectiveness of Losartan and Amlodipine in Hypertensive Patient With Left Ventricular Hypertrophy

Hameed

Rutuparna

Merin

et al. 2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Hypertension is an important worldwide public health challenge because of its high frequency and concomitant risks of cardiovascular and kidney diseases. Left ventricular hypertrophy (LVH) is defined as an increase in the mass of the LV, which can be secondary to an increase in wall thickness, an increase in cavity size, or both. Relevant study reported that LVH is one of the major and independent risk factors for coronary artery disease, heart failure, serious dysrhythmias, and sudden death. Thus, regression of LVH is a primary pharmacologic objective. The objective of this study is to assess the effectiveness of losartan and amlodipine in regression of LVH and to monitor the adverse effects of these drugs on monotherapy. The study also focused to estimate the clinical effectiveness of specified drugs in lowering hypertension. Methods:The study conducted was retrospective, prospective, comparative study extended over 1 year on 28 patients based on inclusion and exclusion criteria.Results: Both these drugs cause regression of LVH with a decrease in LV mass index value; it is seen that amlodipine is better in controlling elevated blood pressure (BP), especially diastolic BP. In statistical analysis, regression of LVH was found to be correlated with reduction of BP. Conclusion:Incidence of adverse effect was found to be prominent in amlodipine group. Thus, losartan was found to be better in regressing LVH than amlodipine.

show abstract

“…Whereas significantly greater LV mass reduction was seen with valsartan compared with amlodipine after 8 months in a Japanese study (along with significant reductions in monocyte-reactive oxygen species and C-reactive protein), 47 no significant reduction was evident after 1 year of olmesartan or amlodipine in a more recently published US study. 103 …”

Section: Clinical Outcomes Beyond Bp Lowering In Rctmentioning

confidence: 99%

Comparing angiotensin II receptor blockers on benefits beyond blood pressure

Siragy

2010

Adv Therapy

View full text Add to dashboard Cite

The renin-angiotensin-aldosterone system (RAAS) is one of the main regulators of blood pressure, renal hemodynamics, and volume homeostasis in normal physiology, and contributes to the development of renal and cardiovascular (CV) diseases. Therefore, pharmacologic blockade of RAAS constitutes an attractive strategy in preventing the progression of renal and CV diseases. This concept has been supported by clinical trials involving patients with hypertension, diabetic nephropathy, and heart failure, and those after myocardial infarction. The use of angiotensin II receptor blockers (ARBs) in clinical practice has increased over the last decade. Since their introduction in 1995, seven ARBs have been made available, with approved indications for hypertension and some with additional indications beyond blood pressure reduction. Considering that ARBs share a similar mechanism of action and exhibit similar tolerability profiles, it is assumed that a class effect exists and that they can be used interchangeably. However, pharmacologic and dosing differences exist among the various ARBs, and these differences can potentially influence their individual effectiveness. Understanding these differences has important implications when choosing an ARB for any particular condition in an individual patient, such as heart failure, stroke, and CV risk reduction (prevention of myocardial infarction). A review of the literature for existing randomized controlled trials across various ARBs clearly indicates differences within this class of agents. Ongoing clinical trials are evaluating the role of ARBs in the prevention and reduction of CV rates of morbidity and mortality in high-risk patients.

show abstract

Comparison of Olmesartan Medoxomil Versus Amlodipine Besylate on Regression of Ventricular and Vascular Hypertrophy

Cited by 13 publications

References 11 publications

Olmesartan Attenuates the Impairment of Endothelial Cells Induced by Oxidized Low Density Lipoprotein through Downregulating Expression of LOX-1

Olmesartan Attenuates the Impairment of Endothelial Cells Induced by Oxidized Low Density Lipoprotein through Downregulating Expression of LOX-1

Assesment of Clinical Effectiveness of Losartan and Amlodipine in Hypertensive Patient With Left Ventricular Hypertrophy

Comparing angiotensin II receptor blockers on benefits beyond blood pressure

Contact Info

Product

Resources

About